Aptevo TherapeuticsAPVO
13F holders, Q1 2025 (March 31)8holders −5
2new positions
7sold out
$1.16avg. 13F price*
At the end of Q1 2025, 8 institutions reported holding Aptevo Therapeutics Inc. (APVO) in their 13F filings, down 5 from Q4 2024. 2 opened new positions and 7 sold out. The largest holders were Geode Capital Management, LLC ($12K), Tower Research Capital LLC (TRC) ($4K) and Clear Street LLC ($3K).
- Company
- Aptevo Therapeutics Inc.
- CUSIP
- 03835L405
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $15K |
| Exits | 7 | $186K |
All 13F filers, Q4 2024 → Q1 2025: 18,379 shares bought and 47,242 shares sold, net −28,863 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Geode Capital Management, LLC | 0.00% | New | 10,526 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +199.7% | 3,255 | $4K |
| Clear Street LLC | 0.00% | New | 2,800 | $3K |
| Bank of America Corp. | 0.00% | Add +57850.0% | 2,318 | $3K |
| SBI Securities Co., Ltd. | 0.00% | Add +435.1% | 701 | $813 |
| BlackRock, Inc. | 0.00% | No change | 24 | $28 |
| Morgan Stanley | 0.00% | Reduce -99.9% | 4 | $4 |
| Osaic Holdings, Inc. | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is APVO's weight in each manager's 13F, not the share of Aptevo Therapeutics Inc. the manager owns.